Compare Globus Medical Inc. Class A Common Stock (GMED) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Weibo Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Weibo Corp trades at $6.43 (market cap $1.62B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 6.3× Weibo Corp's market cap, and Weibo Corp pays a 9.36% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Weibo Corp for 103 Days on average.
| GMED | WB | |
|---|---|---|
Market Cap | $10.25B | $1.62B |
Volume | 1,059,528 | 835,309 |
Sector | Health | Media |
52-Week High | $96.82 | $11.52 |
52-Week Low | $58.33 | $6.33 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $9.76B | $849.15M |
Dividend Yield | — | 9.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Weibo (WB) trades at $6.56, up 0.23% with bearish technical signals despite attractive valuation metrics including a P/E of 5.38 and P/B of 0.4. The company reported Q2 2026 earnings beat with $0.38 EPS versus $0.36 expected, though revenue growth remains modest at 2% year-over-year. Net income margin improved to 17.78% in 2026, while cash flow trends show volatility with a $694 million net outflow in 2024 followed by $408 million inflow in 2025.
Weibo presents as a deep-value opportunity with strong profitability but faces user growth challenges and advertising market headwinds. Analyst consensus is mixed with 41% buy ratings versus 14% sells, reflecting uncertainty about long-term relevance amid competitive pressures. The stock's current valuation discount offers potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
